

Übersicht Urologische Onkologische Studien

Diagnose	Studienkürzel	Studientitel	Sponsor	Studienphase	Rekrutierung	Vertragsbeginn	Vertragsende
Nierenzellkarzinom	W041994	A Phase III, multicenter, randomized, open label study of Atezolizumab in combination with Cabozantinib in Patients with Advanced Renal Cell Carcinoma who experienced disease progression during or after Check Point Inhibitor Treatment	Roche	III	beendet	15.05.2020	
myoinvasives Urothelkarzinom	BLCA01	Eine Studie zum Vergleich der öffentlich verfügbaren Mutationsdaten (TCGA-The Cancer Genom Anatomy Project) mit denen in der regionalen Patientenpopulation unter Verwendung der Roche AVENION Kits und eines blasenspezifischen Sequenzierpanels	Signature Diagnostics GmbH	klinisch diagnostische Studie	laufend	Feb 20	
Nierenzellkarzinom	MK-6482-011	A Phase 3 Study of MK-6482 in Combination with Lenvatinib vs Cabozantinib for second line Treatment of RCC	MSD	III	laufend	04.05.2021	
myoinvasives Urothelkarzinom	MK3475-B15	A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)	MSD	III	laufend	14.05.2021	
myoinvasives Urothelkarzinom	BO42843	A Phase III, multicenter, randomized, open label study of Atezolizumab vs. Placebo as adjuv. therapy in patients with high-risk muscle-invasive bladder cancer who are CTDNA positive following cystectomy	Roche	III	laufend	30.04.2021	
Prostatakarzinom	PCO	Prostate Cancer Outcomes – Compare Et Reduce Variation in DKG zertifizierten Prostatakrebszentren"	k.A.	NIS	laufend	k.A.	
neudiagnostiziert Malignome	COMA19	UKH	NIS	laufend	28.06.2021		
Nierenzellkarzinom	MK-6482-022	A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)	MSD	III	laufend	01.11.2022	
Nierenzellkarzinom+Urothelkarzinom	CARAT	Registerplattform urologische Tumore Clinical Research Platform On Urologic Cancer Treatment And Outcome (CARAT)	iOMEDICA AG	NIS	laufend	08.11.2022	
lokal fortgeschrittenes oder metastasiertes Urothelkarzinom	BO44157	A Phase II, randomized, multicenter, open label, controlled Study of R07247669 alone or in Combination with Tigragolumab vs Atezolizumab in Patients with previously untreated locally advanced or metastatic urothelial bladder cancer who are ineligible for platinum containing chemotherapy	Roche	II	in Vorbereitung		
lokal fortgeschrittenes oder metastasiertes Urothelkarzinom	W044513	A Phase II, multicenter, randomized, open label Study of Tiragolumab+Atezolizumab concurrently or sequentially with chemotherapy in Cisplatin eligible Patients with untreated locally advanced or metastatic urothelial carcinoma	Roche	II	in Vorbereitung		
metastasiertes hormonsensitives Prostatakarzinom	ARASAFE	A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m ² versus 2-weekly Docetaxel 50mg/m ² in combination with Darolutamide + ADT in patients with mHSPC	Friedrich Schiller Universität Jena	III	in Vorbereitung		
Nierenzellkarzinom	CaboCare	noch kein Protokoll	IPSEN	NIS	in Vorbereitung		

nichtinterventionelles Studien
 interventionelle Zulassungsstudien